This report analyzes the worldwide markets for Imaging Agents in US$ Million by the following product segments - Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 55 companies including many key and niche players such as AMAG Pharmaceuticals Inc., Bayer Schering Pharma AG, Bracco Group, Covidien, Cytogen Corp., Daiichi Sankyo Company Limited, Eisai Co., Ltd, GE Healthcare, Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. 

TABLE OF CONTENTS

IMAGING AGENTS									MCP-3336
A GLOBAL STRATEGIC BUSINESS REPORT


                                            CONTENTS



  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS                        1
      Study Reliability and Reporting Limitations                           1
      Disclaimers                                                           2
      Data Interpretation & Reporting Level                                 3
       Quantitative Techniques & Analytics                                  3
      Product Definitions and Scope of Study                                3
       A. Contrast Media                                                    3
         X-Ray Contrast Media                                               3
         Magnetic Resonance Imaging (MRI) Contrast Media                    4
         Ultrasound Contrast Media                                          4
       B. Diagnostic Radiopharmaceuticals                                   4

  2. INDUSTRY OVERVIEW                                                      6
      Medical Imaging Industry Under the Impact of Economic Downturn        6
      Future Prospects                                                      6
      Targeted MRI Imaging - A Game Changer in the Making?                  8
      Developing Countries to Spur Growth                                   8
      A Quick Primer On Imaging Agents                                      8
       Growth Drivers                                                       9
       Growth Inhibitors                                                    10
      Changing Dynamics of Imaging Agents                                   11
      Imaging Agents: Significant Growth Ahead                              12
      Rise of Non-Ionizing Imaging Techniques                               12
       Fusion Imaging Modalities: Greater Clinical Benefits                 13
        Radioactive Isotopes Utilized in PET & SPECT Imaging Procedures     13
       Radiopharmaceuticals-An Exotic Tool                                  14
       Nanomaterials Taking the Center Stage                                14
        Gadolinium Coated Nanoparticles- A Promising Imaging Agent          15
      A Peek Into Pricing Dynamics                                          15
       A Synoptic Overview                                                  15
       Pros & Cons                                                          16
       Positive Factors Driving Prices                                      16
       Negative Factors Bearing Down on Prices                              16
      Reimbursements                                                        17
       “Under the Umbrella”                                                 17
        Europe                                                              17
        United States                                                       17

  3. MARKET TRENDS & ISSUES                                                 19
      Falling Prices Turn On the Heat                                       19
      X-Ray Contrast Media: Declining Sector                                19
      MRI Contrast Media: Playing at Center Court                           19
      Impact Wielded by Ballooning MRI Practices                            19
      Ultrasound Contrast Media: A Rising Star in the Quadrant              20
       Fledging Market Battles Teething Challenges                          21
      PET: A Prime Growth Driver for Radiopharmaceuticals                   21
      Nuclear Medicine: A Potential Growth Avenue for
       Radiopharmaceuticals                                                 22
       Select Cardiology and Oncology Radiopharmaceuticals                  22

  4. COMPETITION                                                            23
      Market Structure                                                      23
      Big Guns in the Emerging MRI Market                                   24
      Bayer Schering Pharma AG: A Pioneering Developer of MRI
       Contrast Agents                                                      24
      Competitive Scenario                                                  25
       Table 1: Worldwide Imaging Agents Market (2009E): Percentage
       Breakdown of Value Sales for Leading Players- GE Healthcare,
       Bracco, Covidien, Bayer Schering Pharma, and Others (includes
       corresponding Graph/Chart)                                           25

       Table 2: X-ray Medical Contrast Media Market Worldwide
       (2009E): Percentage Breakdown of Sales for GE Healthcare,
       Bracco, Covidien, Bayer Schering Pharma and Others (includes
       corresponding Graph/Chart)                                           25

       Table 3: MRI Contrast Media Market Worldwide (2009):
       Percentage Breakdown of Sales for Bayer Schering Pharma, GE
       Healthcare, Bracco, Covidien and Others (includes
       corresponding Graph/Chart)                                           26

       Table 4: Radiopharmaceutical Contrast Media Market Worldwide:
       Percentage Share of Leading Players for 2007 - GE Healthcare,
       Bristol-Myers Squibb, Mallinckrodt/ Covidien, MDS Nordion and
       Others (Revenue Share) (includes corresponding Graph/Chart)          26

  5. TECHNOLOGY BREAKTHROUGHS                                               27
      Molecular Imaging Agents: The Outer Limits                            27
      On Cards: Hyperpolarized Gases as Contrast Agents                     27
      Imaging Agents Make a Welcome Impact in the Field of
       Alzheimer’s Disease                                                  28
      Technetium-99m: A Breakthrough Contrast Agent for CNS Imaging         28
      A New Imaging Agent for Radiopharmaceutical Scans                     28
      Multi-Modal Image Registration: Combating Contrast Medium
       Inconsistencies                                                      28
      Saline Flushes To Help Ensure Accurate Delivery of Contrast
       Agents                                                               29

  6. PRODUCT OVERVIEW                                                       30
      Contrast Agents                                                       30
       Contrast Media: How Do They Function?                                30
        Where Are They Used ?                                               31
       Evolution of Contrast Media: A Profile                               31
        Bismuth Nitrate: Beginning of Contrast Agents                       31
       Imaging Agents: Significant Developments in the Last Fifty Years     32
       Schering Develops First Intravenous Contrast Agent                   32
       MRI: Creating a New Era for Contrast Agents                          32
       A Peek into the Finer Points of Differences Among Contrast Media     32
         Viscosity                                                          32
         Osmolality                                                         33
         Chemotoxicity                                                      33
       Second Generation Non-Ionic Contrast Agents: An Introduction         33
       Choice of the Contrast Medium: A Weighty Decision                    33
       Factors affecting choice of Imaging Agents                           33
      Taxonomy                                                              34
      Types of Contrast Media                                               34
       X-Ray Contrast Medium                                                34
        First Generation High Osmolar Contrast Media                        35
        Second Generation Low Osmolar Contrast Media or LOCM                35
         Table 5: Comparative Analysis of Structure of Non-ionic and
         ionic X-ray Contrast Media                                         35
       MRI Contrast Medium                                                  35
        Role of Contrast Enhancement in MR Angiography (MRA)                37
        MRI Contrast Agents for the Liver                                   37
         Paramagnetic extracellular contrast agents                         37
         Hepatobiliary Gadolinium Chelates                                  37
         Superparamagnetic Iron Oxide Particles                             37
       Ultrasound Contrast Medium                                           37
        Ultrasonographic Contrast Media: What Are They?                     38
        Ultrasound Contrast Enhancement in Cardiology                       39
        Functionalities of Vascular Ultrasound Contrast Agents              39
       Diagnostic Radiopharmaceuticals                                      39
        Key Radioactive Isotopes used as Diagnostic
         Radiopharmaceuticals                                               40
         A Delineate of Diagnostic Radiopharmaceuticals                     41
         Diagnostic Radiopharmaceuticals: A Technical Run-Through           41
         Applications                                                       42

  7. A SEGMENTAL REVIEW                                                     43
      Contrast Media                                                        43
      Popular Brands of Contrast Agents                                     43
       X-ray Contrast Media                                                 44
        Market Scenario                                                     44
       MRI Contrast Media                                                   45
        Market Scenario                                                     44
       Ultrasound Contrast Media                                            45
        Market Overview                                                     45
        Competitive Scenario                                                46
       Diagnostic Radiopharmaceuticals                                      46
        Market Overview                                                     46
       Immunoconjugates                                                     46
        Market Overview                                                     46
        Competitive Scenario                                                47

  8. TECHNOLOGY DYNAMICS                                                    48
      Proprietary Technologies Making Significant In-Roads                  48
       Advanced Magnetics’ Proprietary Colloidal Superparamagnetic
        Particle Technology                                                 48
       Enzon’s Single Chain Antigen-Binding Technology                      48
       Immunomedics’ Antibody Technology                                    48
        First Generation                                                    48
        Second Generation                                                   48
        Third Generation                                                    48
       NeoRx’s “Painting the Target” Technology                             49
        Stage - I                                                           49
        Stage - II                                                          49
        Stage - III                                                         49
       Gas Encapsulation Technology for Ultrasound Contrast Media           49
       Pharmacyclics’ Texaphyrin Technology                                 50
      Regulatory Bodies                                                     50
       Ultrasound Contrast Agents Are Drugs, Not Devices - Rules US FDA     50
      Entry Barriers                                                        50
       Research Driven Markets                                              50
       Highly Competitive Market                                            51
       Economies of Scale                                                   51
      Substitutes in Agents Manufacturing                                   51
       New X-ray Diagnostic Agents                                          51
       Amide-based Macrocyclic Ligands - Potential MRI Agents               51
       Gadolinium (III) Complexes - Potential MRI Contrast Agents           51
       Metal-Containing Compounds Act As Potential Contrast Agents          51
        Therapeutic Applications                                            51
        Diagnostic Applications                                             52
       Magnetic Gels as Potential MRI Contrast Agents                       52
       PFCs as Diagnostic Contrast Agents                                   52

  9. PRODUCT LAUNCHES                                                       53
      GE Healthcare Receives FDA Approval for DaTscan for detecting
       Dopamine Transporters                                                53
      Targeson Launches Targestar® P-HF                                     53
      GE Healthcare Announces Phase II Study Results of
       Flutemetamol, the PET Imaging Agent for Brain Imaging                53
      GE Healthcare Receives FDA Approval for Cysview, An Optical
       Imaging Agent for Cystoscopic Detection of Papillary Bladder
        Cancer                                                              53
      INER Develops Imaging Agents for Cerebral Blood Flow                  54
      Lantheus Medical Imaging Introduces Definity Ultrasound
       Contrast Imaging Agent in India                                      54
      Sanochemia Pharmazeutika Completes DCP Phase of MRT Imaging
       Agent, to Introduce Within Major European Markets by 2011            54
      Bayer Transfers Liver MRI Contrast Medium Resovist Injection
       to I’rom Pharmaceutical                                              54
      GE Healthcare Re-Introduces Contrast Agent, OptisonTM                 54
      Lantheus Medical Imaging Introduces ABLAVAR™ in Canada                55
      VisEn Introduces ProSense® 750 FAST and Neutrophil ElastaseTM
       680 FAST                                                             55
      Bayer Works on Development of MR Contrast Agents for Breast
       Cancer Diagnosis                                                     55
      Lantheus Medical Imaging Introduces ABLAVAR™ MRA Imaging Agent        56
      VisEn Introduces Cat B 680 FAST™ Imaging Agent                        56
      VisEn Medical Introduces GastroSense 750 Fluorescence Imaging
       Agent                                                                56
      VisEn Medical Unveils VivoTag® 645 Red Fluorescent Dye                57
      VisEn Medical Launches VivoTag® 680 XL Fluorescent Dye                57
      AMAG Pharmaceuticals Unveils Superparamagnetic Iron Oxide
       Nanopaticles                                                         57
      MabCure Unveils Monoclonal Antibodies                                 57
      VisEn Medical Introduces ReninSense680TM FAST                         58
      VisEn Medical Introduces New VivoTag® 800 and OsteoSense®
       Imaging Agents                                                       58
      VisEn Medical Introduces Annexin-Vivo 750 Imaging Agent               58
      VisEn Introduces New Fluorescence Molecular Imaging Agent,
       IntegriSense™ 750                                                    59
      Bayer to Launch Primovist™ and Nexavar™ in Japan                      59
      Sanochemia Unveils MR-Lux®                                            60
      VisEn Medical Introduces New Fluorescence in Vivo Imaging
       Agent, IntegriSense                                                  60
      Bayer to Unleash Radiology Management System                          61
      Bayer to Unveil Pre-Filled Contrast-Medium Cartridges for MRI         61

  10. RECENT INDUSTRY ACTIVITY                                              62
      University of Montana Receives Patents for Two New Brain
       Imaging Agents                                                       62
      Eli Lilly Acquires Avid Radiopharmaceuticals                          62
      GE Global Research Secures Multi-Year NIH Grant to Develop
       Nerve Imaging Agent and Imaging System                               62
      Agfa Healthcare Snaps Insight Agents                                  62
      Nordion to Divest MDS Nordion S.A.                                    63
      Sofie Biosciences Secures Funds for Research on Molecular PET
       Imaging Agents                                                       63
      Aposense Signs Collaboration Agreement With Roche                     63
      University of Washington to Collaborate with Cardinal Health
       for Advancement of Molecular Imaging                                 63
      ImaginAb Joins Hand with GE Imanet for Developmental Drug
       Research                                                             64
      Cancer Targeted Technology Inks Agreement with Bayer Pharma
       for Cancer PET Imaging Agent                                         64
      Lantheus Medical Imaging Wins Global Rights for Gadofosveset
       Trisodium                                                            64
      Avid Radiopharmaceuticals Partners with Siemens PETNET
       Solutions for Production of Florbetapir F 18                         64
      VisEn Expands Fluorescence Imaging Intellectual Patent
       Portfolio through Acquisition of Bayer Schering’s Portfolio          65
      Cardinal Health Enters into Partnership with ProVision for
       Cyclotrons                                                           65
      Center for Diagnostic Imaging Sets up New Imaging Center              65
      ImaginAb Signs Sub Licensing Agreement for huJ591 with BZL
       Biologics                                                            65
      Lantheus Medical Imaging and NTP Radioisotopes Sign Agreement
       for Molybdenum-99                                                    66
      Lantheus Medical Imaging Purchases MS-325 Related Rights from
       EPIX Pharmaceuticals                                                 66
      GE Healthcare Inks Agreement with Nycomed                             66
      Photocure Secures Reimbursement Approval for Hexvix in Germany        66
      Agfa HealthCare to Acquire Insight Agents                             67
      Eckert & Ziegler Disinvests FCI Contrast Media Business               67
      Guerbet Signs Distribution Agreement with Draximage for its
       Nuclear Medicine Product Range                                       68
      ImaginAb Signs Sub Licensing Agreement for huJ591 with BZL
       Biologics                                                            68
      Lantheus Medical Imaging and NTP Radioisotopes Sign Agreement
       for Molybdenum-99                                                    68
      Lantheus Medical Imaging Purchases MS-325 Related Rights for
       Select Markets from EPIX Pharmaceuticals                             69
      MDS Nordion, TRIUMF and University of British Columbia Enter
       into Partnership                                                     69
      Alseres Pharmaceuticals Signs Agreement for Special Protocol
       Assessment of Altropane                                              69
      Pharmalucence Wins Approval from FDA for Sestamibi Kit                70
      Covidien Obtains Approval from Health Canada for Sestamibi
       Injection                                                            70
      MDS Nordion Commences Production of CardioGen-82                      70
      Avista Capital Partners Acquires Bristol-Myers Squibb Medical
       Imaging                                                              70
      Amerinet Awards Contract to Bayer HealthCare                          71
      Bristol-Myers Squibb Medical Imaging Changes Name to Lantheus
       Medical Imaging                                                      71
      Bayer Schering Secures FDA Marketing Clearance for Primovist®         72
      Bracco-Eisai Secures Approval for Iomeron® 350 and Iomeron®
       350 Syringe for Use in Dynamic Liver CT                              72
      Covidien Signs Co-Marketing Deal with PETNET over Nuclear
       Medicine Therapies                                                   73
      EPIX Receives FDA Approval for Vasovist                               74
      GE Global and NCI Partner to Speed-up Development of Cancer
       and Heart Disease Diagnosing Nanoparticle Imaging Agents             74
      Lantheus Wins Contract from PPP                                       75
      Sanguine to Take over Rockland                                        75
      Starpharma Holdings Enters into an Agreement with Unilever            75
      GE Healthcare and Cardinal Health Enter Into a Deal                   75
      Jubilant to Take Over DRAXIS                                          76
      MTTI and Bexion to Partner for Nanovesicle                            76
      Otsuka Takes over IPP                                                 76
      Wilex Inks Deal with IBA                                              77
      Cytogen Corporation to Merge Business with EUSA Pharma Inc            77
      Bracco Group Acquires E-Z-EM                                          77
      EPIX Pharmaceuticals to Resubmit New Drug Application (NDA)
       for Vasovist                                                         77
      Bayer Schering, FutureChem Ink Licensing Deal                         78
      NuView Radio Pharmaceuticals Inks Agreement for Non- Invasive
       Imaging Agent                                                        78

  11. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER             79
      Advanced Magnetics Inc Changes Name to AMAG Pharmaceuticals           79
      Bracco Diagnostics Inks Agreement with HealthTrust Purchasing
       Group                                                                79
      Bracco Diagnostics Offers MRI Products to HealthTrust
       Purchasing Group                                                     79
      Bayer HealthCare Offers MRI Contrast Agent to HealthTrust             79
      Bayer HealthCare Extends Contract with Premier                        79
      Bayer HealthCare Sets Off US Operations                               79
      Tyco Healthcare Renamed to Covidien Ltd                               80
      Covidien Offers Imaging Solutions to MedAssets Supply Chain
       Systems                                                              80
      Siemens, M.D. Anderson Cancer Center Set up Research Centre           80
      Bayer, Berlex Merge Operations                                        80
      AION Diagnostics Forays Pre-Clinical Imaging Agent Market             80
      ART Acquires Alerion Biomedical                                       80
      EPIX to Merge with Predix                                             81
      Fujifilm Acquires Stake in Daiichi Radioisotope Laboratories          81
      Bracco Diagnostics Inks Agreement with Amerinet                       81
      Vasovist receives Green Signal in Australia                           81
      AION Diagnostics Develops BioSilicon TM                               81
      Sonazoid Receives Import Approval                                     81
      Schering AG Divests Radiopharmaceutical Business to Ion Beam
       Applications and Institut National des Radioéléments                 82
      Vasovist Receives European Approval                                   82
      Albany Molecular Research Renews Supply Agreement with GE
       Healthcare                                                           82
      QuantRx Biomedical Corp. Acquires Stake in FluoroPharma               82
      Palatin Technologies Withdraws NeutroSpec Imaging Agent               82
      Diosynth Bags Contract to Produce Imaging Agent                       83
      GE Healthcare Signs Marketing Agreement with PhotoCure                83
      DRAXIMAGE Receives the Green Signal in Europe                         83
      Daiichi and Sankyo Sign a Merger Deal                                 83

  12. PRODUCT INTRODUCTIONS IN RECENT PAST - A PERSPECTIVE BUILDER          84
      Insight Agents to Launch Generic Contrast Media Solutions In
       Europe                                                               84
      Researchers Develop First Biocompatible MRI Contrast Agent            84
      Signalomics and Invitrogen Collaborate to Develop Nanocrystal
       Reagents                                                             84
      Schering AG Collaborates with Stanford University to Develop
       Molecular Imaging Agent                                              84
      Schering and Avid to Develop Diagnostic Imaging Agents                84
      US National Institutes of Health Develops two PET Imaging Agents      85

  13. FOCUS ON SELECT PLAYERS                                               86
      AMAG Pharmaceuticals, Inc. (USA)                                      86
      Bayer Schering Pharma AG (Germany)                                    86
      Bracco Group (Italy)                                                  86
      Covidien (USA)                                                        87
      Cytogen Corp. (USA)                                                   87
      Daiichi Sankyo Company Limited (Japan)                                88
      Eisai Co Ltd. (Japan)                                                 88
      GE Healthcare (UK)                                                    88
      Guerbet Group (France)                                                89
      Lantheus Medical Imaging (USA)                                        89

  14. GLOBAL MARKET PERSPECTIVE                                             90
      Table 6: World Recent Past, Current & Future Analysis for
      Imaging Agents by Geographic Region - US, Canada, Japan,
      Europe, Asia-Pacific (excluding Japan), Middle East and Latin
      America Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 2007 through 2015 (includes
      corresponding Graph/Chart)                                            90

      Table 7: World Historic Review for Imaging Agents by
      Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), Middle East and Latin American Markets
      Independently Analyzed with Annual Sales Figures in US$
      Million for Years 2000 through 2006 (includes corresponding
      Graph/Chart)                                                          91

      Table 8: World 11-Year Perspective for Imaging Agents by
      Geographic Region- Percentage Breakdown of Dollar Sales for
      US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
      Middle East and Latin America Markets for Years 2005, 2010 &
      2015 (includes corresponding Graph/Chart)                             92

      Table 9: World Recent Past, Current & Future Analysis for
      Contrast Media by Geographic Region - US, Canada, Japan,
      Europe, Asia-Pacific (excluding Japan), Middle East and Latin
      America Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 2007 through 2015 (includes
      corresponding Graph/Chart)                                            93

      Table 10: World Historic Review for Contrast Media by
      Geographic Region - US, Canada, Japan, Europe, Asia- Pacific
      (excluding Japan), Middle East and Latin American Markets
      Independently Analyzed with Annual Sales Figures in US$
      Million for Years 2000 through 2006 (includes corresponding
      Graph/Chart)                                                          94

      Table 11: World 11-Year Perspective for Contrast Media by
      Geographic Region- Percentage Breakdown of Dollar Sales for
      US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
      Middle East and Latin America Markets for Years 2005, 2010 &
      2015 (includes corresponding Graph/Chart)                             95

      Table 12: World Recent Past, Current & Future Analysis for
      Contrast Media by Product Segments - X-Ray, MRI and Ultrasound
      Markets Independently Analyzed with Annual Sales Figures in
      US$ Million for Years 2007 through 2015 (includes
      corresponding Graph/Chart)                                            96

      Table 13: World Historic Review for Contrast Media by Product
      Segments - X-Ray, MRI and Ultrasound Markets Independently
      Analyzed with Annual Sales Figures in US$ Million for Years
      2000 through 2006 (includes corresponding Graph/Chart)                97

      Table 14: World 11-Year Perspective for Contrast Media by
      Product Segments - Percentage Breakdown of Dollar Sales for
      X-Ray, MRI and Ultrasound Markets for Years 2005, 2010 & 2015
      (includes corresponding Graph/Chart)                                  97

      Table 15: World Recent Past, Current & Future Analysis for
      X-Ray Contrast Media by Geographic Region - US, Canada, Japan,
      Europe, Asia-Pacific (excluding Japan), Middle East and Latin
      America Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 2007 through 2015 (includes
      corresponding Graph/Chart)                                            98

      Table 16: World Historic Review for X-ray Contrast Media by
      Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), Middle East and Latin American Markets
      Independently Analyzed with Annual Sales Figures in US$
      Million for Years 2000 through 2006 (includes corresponding
      Graph/Chart)                                                          99

      Table 17: World 11-Year Perspective for X-Ray Contrast Media
      by Geographic Region- Percentage Breakdown of Dollar Sales for
      US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
      Middle East and Latin America Markets for Years 2005, 2010 &
      2015 (includes corresponding Graph/Chart)                             100

      Table 18: World Recent Past, Current & Future Analysis for MRI
      Contrast Media by Geographic Region - US, Canada, Japan,
      Europe, Asia-Pacific (excluding Japan), Middle East and Latin
      America Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 2007 through 2015 (includes
      corresponding Graph/Chart)                                            101

      Table 19: World Historic Review for MRI Contrast Media by
      Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), Middle East and Latin American Markets
      Independently Analyzed with Annual Sales Figures in US$
      Million for Years 2000 through 2006 (includes corresponding
      Graph/Chart)                                                          102

      Table 20: World 11-Year Perspective for MRI Contrast Media by
      Geographic Region- Percentage Breakdown of Dollar Sales for
      US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
      Middle East and Latin America Markets for Years 2005, 2010 &
      2015 (includes corresponding Graph/Chart)                             103

      Table 21: World Recent Past, Current & Future Analysis for
      Ultrasound Contrast Media by Geographic Region - US, Canada,
      Japan, Europe, Asia-Pacific (excluding Japan), Middle East and
      Latin America Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 2007 through 2015 (includes
      corresponding Graph/Chart)                                            104

      Table 22: World Historic Review for Ultrasound Contrast Media
      by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), Middle East and Latin American Markets
      Independently Analyzed with Annual Sales Figures in US$
      Million for Years 2000 through 2006 (includes corresponding
      Graph/Chart)                                                          105

      Table 23: World 11-Year Perspective for Ultrasound Contrast
      Media by Geographic Region- Percentage Breakdown of Dollar
      Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
      Japan), Middle East and Latin America Markets for Years 2005,
      2010 & 2015 (includes corresponding Graph/Chart)                      106

      Table 24: World Recent Past, Current & Future Analysis for
      Diagnostic Radiopharmaceuticals by Geographic Region - US,
      Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle
      East and Latin America Markets Independently Analyzed with
      Annual Sales Figures in US$ Million for Years 2007 through
      2015 (includes corresponding Graph/Chart)                             107

      Table 25: World Historic Review for Diagnostic
      Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
      Europe, Asia-Pacific (excluding Japan), Middle East and Latin
      American Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 2000 through 2006 (includes
      corresponding Graph/Chart)                                            108

      Table 26: World 11-Year Perspective for Diagnostic
      Radiopharmaceuticals by Geographic Region- Percentage
      Breakdown of Dollar Sales for US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), Middle East and Latin America
      Markets for Years 2005, 2010 & 2015 (includes corresponding
      Graph/Chart)                                                          109

  15. THE UNITED STATES                                                     110
      A.Market Analysis                                                     110
        Outlook                                                             110
        Imaging Centers Feel the Heat During Recession                      110
        Growth Stimulants                                                   111
        Dynamics of Pricing                                                 111
        Diagnostic Radiopharmaceuticals                                     112
         Market Scenario                                                    112
         Availability of Isotopes: A Tough Challenge                        112
        Radiopharmaceuticals to Drive Growth                                112
        Competitive Analysis - Imaging Market                               113
        Reimbursement Issues                                                113
         Medicare                                                           113
         Magnetic Resonance Imaging                                         114
        Regulatory Environment                                              115
         Provisions Regarding Off-Label Usage of Contrast Media             116
        Contrast Media                                                      116
         X-ray Contrast Media                                               116
         MRI Contrast Media                                                 116
          Market Scenario                                                   116
        Managed Care Vs MRI Technology Diffusion                            117
         Ultrasound Contrast Media                                          117
      B.Market Analytics                                                    117
        Table 27: US Recent Past, Current & Future Analysis for
        Imaging Agents by Product Segment - Contrast Media (X-ray,
        MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2007 through 2015 (includes corresponding
        Graph/Chart)                                                        117

        Table 28: US Historic Review for Imaging Agents by Product
        Segment - Contrast Media (X-ray, MRI and Ultrasound) and
        Diagnostic Radiopharmaceuticals Independently Analyzed with
        Annual Sales Figures in US$ Million for Years 2000 through
        2006 (includes corresponding Graph/Chart)                           118

        Table 29: US 11-Year Perspective for Imaging Agents by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets for Years 2005, 2010 & 2015
        (includes corresponding Graph/Chart)                                119

  16. CANADA                                                                120
      A.Market Analysis                                                     120
        Outlook                                                             120
        Diagnostic Equipment Market                                         120
         LOCM Products Approved in Canada                                   120
      B.Market Analytics                                                    121
        Table 30: Canadian Recent Past, Current & Future Analysis
        for Imaging Agents by Product Segment- Contrast Media
        (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets Independently Analyzed with
        Annual Sales in US$ Million for Years 2007 through 2015
        (includes corresponding Graph/Chart)                                121

        Table 31: Canadian Historic Review for Imaging Agents by
        Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
        and Diagnostic Radiopharmaceuticals Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2006 (includes corresponding Graph/Chart)                   122

        Table 32: Canadian 11-Year Perspective for Imaging Agents by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets for Years 2005, 2010 & 2015
        (includes corresponding Graph/Chart)                                123

  17. JAPAN                                                                 124
      A.Market Analysis                                                     124
        Outlook                                                             124
        Reimbursement Issues                                                124
      B.Market Analytics                                                    125
        Table 33: Japanese Recent Past, Current & Future Analysis
        for Imaging Agents by Product Segment - Contrast Media
        (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets Independently Analyzed with
        Annual Sales in US$ Million for Years 2007 through 2015
        (includes corresponding Graph/Chart)                                125

        Table 34: Japanese Historic Review for Imaging Agents by
        Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
        and Diagnostic Radiopharmaceuticals Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2006 (includes corresponding Graph/Chart)                   126

        Table 35: Japanese 11-Year Perspective for Imaging Agents by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets for Years 2005, 2010 & 2015
        (includes corresponding Graph/Chart)                                127

  18. EUROPE                                                                128
      A.Market Analysis                                                     128
        Outlook                                                             128
        Trends                                                              128
         Reimbursement                                                      128
         Outsourcing of Imaging Diagnostics                                 129
        Distribution Structure                                              129
         Direct Sales                                                       129
         License Agreements                                                 129
         Distribution Agreements                                            130
         A Price Sensitive Market                                           130
        Macro Environment                                                   130
         Germany                                                            130
         France                                                             130
         Spain & Italy                                                      131
         Scandinavia                                                        131
      B.Market Analytics                                                    132
        Table 36: European Recent Past, Current & Future Analysis
        for Imaging Agents by Geographic Region - France, Germany,
        UK, Italy, Spain, Russia and Rest of Europe Markets
        Independently Analyzed with Annual Sales in US$ Million for
        Years 2007 through 2015 (includes corresponding Graph/Chart)        132

        Table 37: European Historic Review for Imaging Agents by
        Geographic Region - France, Germany, UK, Italy, Spain,
        Russia and Rest of Europe Markets Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2006 (includes corresponding Graph/Chart)                   133

        Table 38: European 11-Year Perspective for Imaging Agents by
        Geographic Region - Percentage Breakdown of Dollar Sales for
        France, Germany, UK, Italy, Spain, Russia and Rest of Europe
        Markets for Years 2005, 2010 & 2015 (includes corresponding
        Graph/Chart)                                                        134

        Table 39: European Recent Past, Current & Future Analysis
        for Imaging Agents by Product Segment - Contrast Media
        (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets Independently Analyzed with
        Annual Sales in US$ Million for Years 2007 through 2015
        (includes corresponding Graph/Chart)                                135

        Table 40: European Historic Review for Imaging Agents by
        Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
        and Diagnostic Radiopharmaceuticals Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2006 (includes corresponding Graph/Chart)                   136

        Table 41: European 11-Year Perspective for Imaging Agents by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets for Years 2005, 2010 & 2015
        (includes corresponding Graph/Chart)                                137

  18a.FRANCE                                                                138
      A.Market Analysis                                                     138
        Outlook                                                             138
        Growth Stimulants                                                   138
      B.Market Analytics                                                    138
        Table 42: French Recent Past, Current & Future Analysis for
        Imaging Agents by Product Segment - Contrast Media (X-ray,
        MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2007 through 2015 (includes corresponding
        Graph/Chart)                                                        138

        Table 43: French Historic Review for Imaging Agents by
        Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
        and Diagnostic Radiopharmaceuticals Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2006 (includes corresponding Graph/Chart)                   139

        Table 44: French 11-Year Perspective for Imaging Agents by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Contrast Media (X-ray, MRI and Ultrasound) & Diagnostic
        Radiopharmaceuticals Markets for Years 2005, 2010 & 2015
        (includes corresponding Graph/Chart)                                140

  18b.GERMANY                                                               141
      A.Market Analysis                                                     141
        Outlook                                                             141
      B.Market Analytics                                                    141
        Table 45: German Recent Past, Current & Future Analysis for
        Imaging Agents by Product Segment - Contrast Media (X-ray,
        MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2007 through 2015 (includes corresponding
        Graph/Chart)                                                        141

        Table 46: German Historic Review for Imaging Agents by
        Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
        and Diagnostic Radiopharmaceuticals Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2006 (includes corresponding Graph/Chart)                   142

        Table 47: German 11-Year Perspective for Imaging Agents by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets for Years 2005, 2010 & 2015
        (includes corresponding Graph/Chart)                                143

  18c. ITALY                                                                144
       Market Analysis                                                      144
        Table 48: Italian Recent Past, Current & Future Analysis for
        Imaging Agents by Product Segment - Contrast Media (X-ray,
        MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2007 through 2015 (includes corresponding
        Graph/Chart)                                                        144

        Table 49: Italian Historic Review for Imaging Agents by
        Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
        and Diagnostic Radiopharmaceuticals Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2006 (includes corresponding Graph/Chart)                   145

        Table 50: Italian 11-Year Perspective for Imaging Agents by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets for Years 2005, 2010 & 2015
        (includes corresponding Graph/Chart)                                146

  18d.THE UNITED KINGDOM                                                    147
      A.Market Analysis                                                     147
        Outlook                                                             147
      B.Market Analytics                                                    147
        Table 51: UK Recent Past, Current & Future Analysis for
        Imaging Agents by Product Segment - Contrast Media (X-ray,
        MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2007 through 2015 (includes corresponding
        Graph/Chart)                                                        147

        Table 52: UK Historic Review for Imaging Agents by Product
        Segment - Contrast Media (X-ray, MRI and Ultrasound) and
        Diagnostic Radiopharmaceuticals Independently Analyzed with
        Annual Sales Figures in US$ Million for Years 2000 through
        2006 (includes corresponding Graph/Chart)                           148

        Table 53: UK 11-Year Perspective for Imaging Agents by
        Product Segment Percentage Breakdown of Dollar Sales for
        Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets for Years 2005, 2010 & 2015
        (includes corresponding Graph/Chart)                                149

  18e. SPAIN                                                                150
       Market Analysis                                                      150
        Table 54: Spanish Recent Past, Current & Future Analysis for
        Imaging Agents by Product Segment - Contrast Media (X-ray,
        MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2007 through 2015 (includes corresponding
        Graph/Chart)                                                        150

        Table 55: Spanish Historic Review for Imaging Agents by
        Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
        and Diagnostic Radiopharmaceuticals Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2006 (includes corresponding Graph/Chart)                   151

        Table 56: Spanish 11-Year Perspective for Imaging Agents by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets for Years 2005, 2010 & 2015
        (includes corresponding Graph/Chart)                                152

  18f. RUSSIA                                                               153
       Market Analysis                                                      153
        Table 57: Russian Recent Past, Current & Future Analysis for
        Imaging Agents by Product Segment -Contrast Media (X-ray,
        MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
        Markets Independently Analyzed with Annual Sales in US$
        Million for Years 2007 through 2015 (includes corresponding
        Graph/Chart)                                                        153

        Table 58: Russian Historic Review for Imaging Agents by
        Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
        and Diagnostic Radiopharmaceuticals Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2006 (includes corresponding Graph/Chart)                   154

        Table 59: Russian 11-Year Perspective for Imaging Agents by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets for Years 2005, 2010 & 2015
        (includes corresponding Graph/Chart)                                155

  18g. REST OF EUROPE                                                       156
       Market Analysis                                                      156
        Table 60: Rest of Europe Recent Past, Current & Future
        Analysis for Imaging Agents by Product Segment - Contrast
        Media (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets Independently Analyzed with
        Annual Sales in US$ Million for Years 2007 through 2015
        (includes corresponding Graph/Chart)                                156

        Table 61: Rest of Europe Historic Review for Imaging Agents
        by Product Segment - Contrast Media (X-ray, MRI and
        Ultrasound) and Diagnostic Radiopharmaceuticals
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 2000 through 2006 (includes corresponding
        Graph/Chart)                                                        157

        Table 62: Rest of Europe 11-Year Perspective for Imaging
        Agents by Product Segment - Percentage Breakdown of Dollar
        Sales for Contrast Media (X-ray, MRI and Ultrasound) and
        Diagnostic Radiopharmaceuticals Markets for Years 2005, 2010
        & 2015 (includes corresponding Graph/Chart)                         158

  19. ASIA-PACIFIC                                                          159
      A.Market Analysis                                                     159
        Outlook                                                             159
        MRI Market in Asia                                                  159
        ANSTO: Leading the Radiopharmaceuticals Market                      159
        India - A High Potential Market                                     159
      B.Market Analytics                                                    160
        Table 63: Asia-Pacific Recent Past, Current & Future
        Analysis for Imaging Agents by Product Segment - Contrast
        Media (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets Independently Analyzed with
        Annual Sales in US$ Million for Years 2007 through 2015
        (includes corresponding Graph/Chart)                                160

        Table 64: Asia-Pacific Historic Review for Imaging Agents by
        Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
        and Diagnostic Radiopharmaceuticals Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2006 (includes corresponding Graph/Chart)                   161

        Table 65: Asia-Pacific 11-Year Perspective for Imaging
        Agents by Product Segment - Percentage Breakdown of Dollar
        Sales for Contrast Media (X-ray, MRI and Ultrasound) and
        Diagnostic Radiopharmaceuticals Markets for Years 2005, 2010
        & 2015 (includes corresponding Graph/Chart)                         162

  20. THE MIDDLE EAST                                                       163
       Market Analysis                                                      163
        Table 66: Middle East Recent Past, Current & Future Analysis
        for Imaging Agents by Product Segment - Contrast Media
        (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets Independently Analyzed with
        Annual Sales in US$ Million for Years 2007 through 2015
        (includes corresponding Graph/Chart)                                163

        Table 67: Middle East Historic Review for Imaging Agents by
        Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
        and Diagnostic Radiopharmaceuticals Independently Analyzed
        with Annual Sales Figures in US$ Million for Years 2000
        through 2006 (includes corresponding Graph/Chart)                   164

        Table 68: Middle East 11-Year Perspective for Imaging Agents
        by Product Segment - Percentage Breakdown of Dollar Sales
        for Contrast Media (X-ray, MRI and Ultrasound) and
        Diagnostic Radiopharmaceuticals Markets for Years 2005, 2010
        & 2015 (includes corresponding Graph/Chart)                         165

  21. LATIN AMERICA                                                         166
      A.Market Analysis                                                     166
        Private Sector Boosts Healthcare Segment                            166
      B.Market Analytics                                                    166
        Table 69: Latin American Recent Past, Current & Future
        Analysis for Imaging Agents by Product Segment - Contrast
        Media (X-ray, MRI and Ultrasound) and Diagnostic
        Radiopharmaceuticals Markets Independently Analyzed with
        Annual Sales in US$ Million for Years 2007 through 2015
        (includes corresponding Graph/Chart)                                166

        Table 70: Latin American Historic Review for Imaging Agents
        by Product Segment - Contrast Media (X-ray, MRI and
        Ultrasound) and Diagnostic Radiopharmaceuticals
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 2000 through 2006 (includes corresponding
        Graph/Chart)                                                        167

        Table 71: Latin American 11-Year Perspective for Imaging
        Agents by Product Segment - Percentage Breakdown of Dollar
        Sales for Contrast Media (X-ray, MRI and Ultrasound) and
        Diagnostic Radiopharmaceuticals Markets for Years 2005, 2010
        & 2015 (includes corresponding Graph/Chart)                         168


 COMPETITIVE LANDSCAPE
     
     Total Companies Profiled: 55 (including Divisions/Subsidiaries - 71)

     ------------------------------------------
     Region/Country                     Players
     ------------------------------------------
     The United States                    37
     Canada                                3
     Japan                                 6
     Europe                               19
      France                               2
      Germany                              6
      The United Kingdom                   3
      Italy                                2
      Rest of Europe                       6
     Asia-Pacific (Excluding Japan)        5
     Africa                                1
     ------------------------------------------